Intellia Therapeutics, Inc., a genome editing company, is taking a targeted approach to the development of curative therapeutics. The company's in vivo programs are focused on a variety of potential treatments, including NTLA-2001, currently in Phase 1 clinical trial for the treatment of transthyretin amyloidosis, and NTLA-2002 for the treatment of hereditary angioedema. Other product candidates include NTLA-2003 for alpha-1 antitrypsin deficiency-liver disease, NTLA-3001 for alpha-1 antitrypsin deficiency-lung disease, and NTLA-6001 for CD30+ lymphomas. Hemophilia A and hemophilia B are also key areas of focus for the company, as are ex vivo pipeline treatments like NTLA-5001 for acute myeloid leukemia. Intellia Therapeutics is also developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition to its extensive research and development efforts, Intellia Therapeutics offers tools like the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company has licensed and collaborated on numerous projects, including co-developing potential treatments for hemophilia A and hemophilia B with Regeneron Pharmaceuticals, Inc. and developing allogeneic universal CAR-T cell therapies with AvenCell Therapeutics, Inc. It also has a license and collaboration agreement with Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of B cell-mediated autoimmune diseases. Other collaborators include ONK Therapeutics, Ltd. and Novartis Institutes for BioMedical Research, Inc. Intellia Therapeutics was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Intellia Therapeutics's ticker is NTLA
The company's shares trade on the NASDAQ stock exchange
They are based in Cambridge, Massachusetts
There are 51-200 employees working at Intellia Therapeutics
It is intelliatx.com
Intellia Therapeutics is in the Healthcare sector
Intellia Therapeutics is in the Biotechnology industry
The following five companies are Intellia Therapeutics's industry peers: